PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
30971955-11	2019	Treatment with gliclazide 10 mg/kg reduced MPO activity (p < 0.001), MDA levels (p < 0.001) and NFkappaB NLS P50 (p < 0.05) protein levels, resulting in low immunostaining to Cox-2, iNOS (p < 0.05), NFkappaB P65 (p < 0.05), and negative immunoreaction to MMP-2 (p < 0.001).	Gliclazide	15-25	myeloperoxidase	Homo sapiens	43-46